The global aneurysm diagnostic and treatment market is anticipated to grow at a considerable CAGR of 12% during the forecast period. The rising change in lifestyle of people such as lack of physical activity, consumption of alcohol, smoking, and consumption of tobacco, inadequate diet, rising prevalence of hypertension cases, technological advancement in the devices for surgery, and government approvals is driving the global Aneurysms diagnostic and treatment market during the forecast period. The key companies across the globe are highly inclined toward the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace. For instance, in August 2020, Raumedic AG announced that it is planning to expand its medical tubing production capacities at its site in Germany. The expansion was intended to meet the increased demand for components used in infusion and feeding applications.
Apart from this, in November 2020, Braile Biomedica received the CE mark, which is a necessary certificate for the commercialization of products throughout European territory and other countries. Additionally, the company is planning a product launch for Europe and other countries while evaluating opportunities to expand the portfolio with the CE registration.
Browse the full report description of "Global Aneurysm Diagnostic And Treatment Market Size, Share & Trends Analysis Report by Location (Aortal Aneurysm, Cerebral Aneurysm, Peripheral Aneurysm, Popliteal Aneurysm, Splenic Aneurysm, Mesenteric Aneurysm, and Others), by Bulge Shape (Fusiform Aneurysm and Saccular Aneurysm), by Treatment Approach (Open Surgery, Endovascular Stent Graft Surgery, and Medications), by Diagnosis Method (CT Scans and MRI, X-Ray), and by End-Users (Hospitals, Research Institute, and Diagnosis Institutes) Forecast Period (2022-2028)" at https://www.omrglobal.com/industry-reports/aneurysm-diagnostic-and-treatment-market
In November 2019, Terumo Corporation acquired Aortica Corp., which is a U. S based company with a focus on advancing the science of personalized vascular therapy. Aortica developed planning software to match fenestration on endograft with locations of each artery during fenestrated endovascular aortic repair (FEVAR). The advancement in technology was intended to improve graft anchoring and minimize the risks of migration which can be developed from the endovascular treatment of Abdominal Aortic Aneurysms. In March 2019, PDS Biotechnology Corp. announced the closing of its merger with Edhe Therapeutics Inc. The Edge therapeutics will operate ad PDS Biotechnology Corporation and the products will be under the ticker symbol PDSB. Thus, the mergers & acquisitions, partnerships by the major players, and new and innovative product development in the aneurysms diagnostic and treatment market are driving the growth during the forecast period.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Terumo Corporation, Bentley, Cardinal Health, Indospan Ltd, PDS Biotechnology, and Raumedic AG.
Key questions addressed by the report
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
Global Market Report Aneurysm Diagnostic and Treatment Segment
By Location
By Bulge Shape
By Treatment Approach
By Diagnosis Method
By End-Users
Global Aneurysm Diagnostic and Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/aneurysm-diagnostic-and-treatment-market